Clinical trial · Interventional
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
NCT00237172CI-TRIAL-00006823completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a extension study of CSTI571B1201 study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib Mesylate | Drug | Imatinib Mesylate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Imatinib Mesylate
- description
- 400 mg once daily
- interventionNames
- Drug: Imatinib Mesylate
Primary outcomes (1)
- measure
- To study the antineoplastic effect of the investigational drug.
Secondary outcomes (1)
- measure
- To study the safety and pharmacokinetics of the investigational drug.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: \- Patients who completed the CSTI571B1201 study Exclusion Criteria: \- Other protocol-defined inclusion / exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.